Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MRX-502: Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC) - MARCH-PFIC

Next Previous
Trial Profile

MRX-502: Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC) - MARCH-PFIC

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Maralixibat (Primary)
  • Indications Intrahepatic cholestasis
  • Focus Registrational; Therapeutic Use
  • Acronyms MARCH; MARCH-PFIC
  • Sponsors Mirum Pharmaceuticals

Most Recent Events

  • 28 Apr 2025 According to a Mirum Pharmaceuticals Media Release, company will present (Poster presentations) data from this trial at ESPGHAN congresses held on Friday, May 16 from 3:30-4:20pm EST.
  • 28 Apr 2025 According to a Mirum Pharmaceuticals Media Release, company will present data from this trial at ESPGHAN congresses held on Saturday, May 17 from 1:10-2:40pm EEST.
  • 18 Dec 2024 According to a CANbridge Pharmaceuticals media release, company announced the marketing approval of Livmarli by the Taiwan Food and Drug Administration (TFDA) for Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis (PFIC) patients aged 3 months and older.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top